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Summary. In 1981 generalized anaphylaxis was registered 
on 166 occasions in Dutch general and academic hospitals. 
Clinical details of 120 of those patients revealed that in 107 
anaphylaxis was either probable (n=90)  or possible 
(n = 17), whereas in 13 cases some other reaction than an- 
aphylaxis had occurred. The series of confirmed cases 
contained 46 men and 61 women, with mean ages of 47 y 
and 48 y, respectively. 
There was a complete recovery in 102 patients and two 
patients died. Hypotension was present in 79 cases (74%), 
dyspnoea in 34 cases (32%) and a skin reaction, mainly ur- 
ticaria, erythema or angioedema, was ment ioned in 
62 cases (58%). Most cases of anaphylaxis were drug-in- 
duced (76%), the main causes being the analgesic gla- 
fenine and contrast media. Glafenine was mentioned as 
the cause in 36% of all admissions for drug-induced an- 
aphylaxis. Only 3.7% of cases had been reported to the 
voluntary reporting scheme of the Netherlands Centre for 
Monitoring of Adverse Reactions to Drugs. 
On  the basis of reimbursement data, the risk of devel- 
oping severe anaphylaxis to glafenine was estimated at 
11.7-19.3-fold relative to indomethacin, and 13.4-20.2- 
fold relative to oral penicillins. 
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Anaphylact ic reactions are severe, often life-threatening 
allergic episodes. The frequency of anaphylaxis during 
use of drugs is often unknown, but some drugs appear to 
carry a greater isk of provoking an anaphylactic attack 
than others. Since the analgesic agent glafenine was intro- 
duced on the Dutch market in 1967, it has been the most 
frequently reported cause of drug-induced anaphylaxis in 
The Netherlands. Marked and variable underreporting, 
however, means that such reports cannot be used to assess 
incidence or relative risk. To estimate the relative risk of 
severe anaphylaxis to glafenine compared to other drugs, 
a study has been performed which made use of a central 
hospital diagnosis ystem. It showed that glafenine was in- 
deed a major cause of drug-induced anaphylaxis. The will- 
ingness of Dutch specialists to provide anonymized clini- 
cal details on request, suggests that the methods used 
might be suitable for other post-marketing surveillance 
studies. 
Material and methods 
The Dutch Centre for Health Care Information is a non-profit or- 
ganization, which manages 10 nationwide healthcare information 
systems on its own behalf, or at the request of third parties. One of 
the systems, acomputerized register of hospital diagnoses, files up to 
10 diagnoses per patient admission. Registration of the principal di- 
agnosis is obligatory, but the remaining additional diagnoses are 
filed by the hospital on a voluntary basis. All Dutch general and 
university hospitals participate in the scheme. The data are con- 
fidential and are not used for reimbursement procedures. All diag- 
noses are coded according to the International C assification of Dis- 
eases (ICD-9-CM). 
From these data, a separate file was made of all admissions in 
1981 in which one or more of the following ICD-diagnoses were reg- 
istered: 995.0 (anaphylactic shock, including allergic shock, anaphy- 
lactic reaction and anaphylaxis), 995.4 (shock due to anaesthesia) 
and 999.4 (anaphylactic shock due to serum). The specialists in- 
volved in the treatment of the patients were sent a request for de- 
tailed clinical information and for a copy of the discharge summary. 
Each individual case history was analyzed for symptoms, the 
most likely cause and the probability of it having been an anaphylac- 
tic reaction [1]. An anaphylactic reaction was defined as any reac- 
tion, which occurred within 1 h after exposure to any cause, and 
which consisted of involvement of one or more of the following 
organ systems: 
1. circulatory collapse or hypotension (systolic blood pres- 
sure < 100 mm Hg) and symptoms compatible with hypotension 
2. respiratory dyspnoea, e.g. due to laryngeal oedema or spasm, 
bronchospasm 
3. skin urticaria, angioedema, erythematous rash 
4. gastrointestinal system nausea, vomiting, diarrhoea, urge to de- 
faecate 
An anaphylactic reaction was considered "probable" if the symp- 
toms met the criteria defined above, and if the reaction had occurred 
within 60 min of dosing or if the temporal relationship was not quan- 
tiffed but was cited as "immediately" or"shortly" after administra- 
tion. Gastrointestinal symptoms as the only clinical manifestation, 
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however, were not  classified as anaphylaxis. In cases with circulatory 
failure as the sole sign or symptom, acase history was only classified 
as 'anaphylaxis' if cardiac auses had been excluded, and if a vasova- 
gal reaction was considered unlikely. An anaphylactic reaction was 
considered "possible" if the symptoms were consistent with anaphy- 
laxis, and if the reaction occurred within 120 min. An anaphylactic 
reaction was considered as "severe" if it was generalized or poten- 
tially life-threatening. No distinction was made between anaphylac- 
tic and anaphylactoid reactions. 
In those cases in which a drug was the most likely cause, a check 
was made of whether they had been reported to the national adverse 
reaction monitoring centre. This was done by comparison both of 
the date of birth of the otherwise anonymized patient and the date of 
onset of the reaction. 
Based on these admission figures, an estimate was made of the 
relative risk of developing severe anaphylaxis to glafenine (G) as 
compared to indomethacin (I), to nitrofurantoin (N) and to oral 
penicillins (OP). In 1981 the marketed oral penicillins were amoxy- 
cillin, ampicillin, bacampicillin, carindacillin, cloxacillin, dicloxacil- 
lin, phenethicillin, phenoxymethylpenicillin, flucloxacillin, and piv- 
mecillinam. The relative risk was estimated by dividing the ratio of 
the numbers of admissions attributed to glafenine and to indometh- 
acin [Adm(G/I)], nitrofurantoin [Adm(G/N)] and penicillins 
[Adm(G/OP)] to the ratio of the reimbursement figures of these 
drugs [Reimb(G/I), Reimb(G/N) and Reimb(G/OP)]. The result- 
ing relative risk estimates were Adm(G/I)/Reimb(G/I), 
Adm(G/N)/Reimb(G/N) and Adm(G/OP)/Reimb(G/OP), respec- 
tively. The reimbursement data were obtained from the Association 
of Social Health Insurance Funds in The Netherlands, which has a 
file of drug reimbursement data, based on 71% of the actual reim- 
bursement figures. A calculation was made of the 95% confidence 
intervals of the relative risk by the test-based method [2]. 
Results 
The file comprised 166 recorded admissions in 1981. The 
code 995.0 was used 152 times in Dutch hospitals, either as 
the principal diagnosis (n = 115) or as an additional diag- 
nosis (n = 37). Code 995.4 was filed 13 times as the princi- 
pal (n = 3) or as an additional diagnosis (n = 10), and code 
999.4 was registered once (as the principal diagnosis). To 
the request for clinical details, aresponse was received for 
136 cases (82%). In one instance, the specialist refused to 
give details; in 8 cases the medical records could not be 
found; in two cases, the episode of anaphylaxis had oc- 
curred in 1980; and in another case, one person had been 
admitted twice. In four cases the information obtained 
was too scanty to be analysed. All these cases were ex- 
cluded from the analysis. 
In the remaining 120 cases anaphylaxis was regarded as 
'probable' in 90 cases, 'possible' in 17 cases, and 'unlikely' 
in 13 cases. In the latter group only 6 cases had been mis- 
classified; seven patients had developed shock during an- 
aesthesia (code 995.4) and this is not necessarily an an- 
aphylactic reaction. 
The 107 likely (probable and possible) cases of anaphy- 
laxis involved 46 men and 61 women, with mean ages of 
47 y (range 4-80 y; SD 17.6) and 48 y (range 9-80 y; 
SD 19.2), respectively. In 56 cases (52.3%) anaphylaxis 
was the reason for admission, and 46 patients (43%) had 
developed the reaction to a procedure during admission 
(n = 22) or in the outpatient department (n= 24). This in- 
formation was not available for 5 patients. The reaction 
was severe (as defined above) in all 107 patients. Re- 
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covery was complete in 102 patients, 2 patients died (1 at- 
tributed to dextran and 1 to contrast medium), and in 
3 cases the outcome was not clearly stated. The large ma- 
jority of patients had been treated, mainly by intravenous 
or subcutaneous administration of adrenaline and with 
corticosteroids. 
The following symptoms were mentioned in the dis- 
charge summaries: hock or moderate hypotension were 
present in 79 (74%), and absent from 13 (12%) patients; 
dyspnoea was observed in 34 (32%), and was absent from 
39 (36%) patients; a skin reaction was noted in 62 (58%), 
and was absent from 16 (15%) patients. Gastrointestinal 
symptoms had been present in 25% of patients. 
A frequency table shows that drugs were the most im- 
portant cause of anaphylaxis occurring in hospital or as a 
reason for admission (Table 1). Of the 82 patients with a 
drug-induced cause listed in this table, 31 (38%) had used 
the drug before, whereas 2 patients had used the sus- 
pected agent for the first time. In the remaining 49 cases 
(60%), this was not clearly stated. Eleven of the 82 pa- 
tients had a similar, but usually milder eaction previously. 
The most frequently reported causes were glafenine and 
contrast media (Table 2). For obvious reasons, most in- 
stances of anaphylaxis to contrast media occurred uring 
hospital admissions or out-patient procedures. A separate 
analysis of all cases of anaphylaxis as a reason for ad- 
mission from outside hospitals howed that glafenine was 
implicated in 21% of all admissions, and that it accounted 
for 34% of all drug-induced causes (Table 3). A separate 
analysis of all 'probable' cases did not change this percent- 
age. 
An estimate of the risk of developing anaphylaxis (as a 
reason for admission), relative to indomethacin, itrofu- 
rantoin and oral penicillins derived from the main causes 
in Table 3, is shown in Table 4. The ratios of the reimbur- 
Table 1. Causes of anaphylaxis which occurred uring admission, or 
which were the reason for admission to hospital 
Cause number (%) 
Drugs 82 (76%) 
Food 6 (6%) 
Insects 9 (8%) 
Other causes" 4 (4%) 
Unknown 6 (6%) 
Total: 107 (100%) 
other causes: exercise (n = 2), occupation (dyes; n = 1), cats/pollen 
(n = 1) 
Table 2. Most frequently notified drug-induced causes of anaphy- 
laxis during admission, or as a reason for admission to Dutch hospi- 
tals (1981) ~ 
Drugs Number (%) 
Contrast media 28 (34%) 
Glafenine 14 (17%) 
Desensitisation allergens 9 (11% ) 
Propyphenazone 5 (6%) 
Dextrans 4 (5%) 
Benzylpenicillin 2 (3%) 
Nitrofurantoin 2 (3%) 
" Only causes which were noted more than once 
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Table 3. Causes of anaphylaxis a  a reason for admission i 1981 a
Causes Total number (%) Drug-induced 
causes (%) 
Food 6 (10.6%) 
Insects 9 (16.1%) 
Other causes 3 (5.4%) 
Unknown 3 (5.4%) 
Glafenine 12 (21.4%) 34.3% 
Desensitisationallergens 7 (12.5%) 20.0% 
Propyphenazone 5 (8.8%) 14.3% 
Nitrofurantoin 2 (3.6%) 5.8% 
Acetylsalicylic a id 2 (3.6%) 5.8% 
Nalidixic acid 1 (1.8%) 2.8% 
Corticotropin 1 (1.8%) 2.8% 
Tetracosactide 1 (1.8%) 2.8% 
Phenethicillin 1 (1.8%) 2.8% 
Indomethacin 1 (1.8%) 2.8% 
Oxyphenbutazone 1 (1.8%) 2.8% 
Antihistamines 1 (1.8%) 2.8% 
Total 56 (100%) 100% 
a Anaphylaxis during admission, or during procedures inthe outpa- 
tient department are excluded 
sement  figures, which were used as the denominators  in 
the relat ive risk est imates, are also shown. No compar ison 
was made with the other  drugs in Table 3 because of the 
risk of confounding by indication, e.g. antihistamines, al- 
lergens, cort icotropin and tetracosact ide; the absence of 
re imbursement  figures for oxyphenbutazone (not regis- 
tered),  acetylsal icyl ic acid and propyphenazone ( 'over- 
the-counter '  preparat ions) ;  and, the low prescr ipt ion rate 
of nal idixic acid. It is clear from these figures that gla- 
fenine was the most frequent ly incr iminated agent. A1- 
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though Table 4 suggests that n i t rofurantoin also appears  
to be a common cause, it should be noted that in one of the 
two repor ted cases there may have been an acute lung re- 
action rather  than anaphylaxis.  
Of the 82 cases with a drug- induced cause, 3 (3.7%) 
had been repor ted to the nat ional  Adverse  React ion 
Moni tor ing Centre. 73 cases (89%) had not been re- 
ported,  and informat ion was not avai lable for 6 cases. 
Discussion 
The data for 1981 were analysed because it was the most 
recent year  in the per iod in which anaphylaxis to gla- 
fenine was frequent ly repor ted and in which the drug was 
extensively used in The Nether lands.  With decl ining use, 
a low prevalence of exposure may make it difficult to es- 
t imate the relat ive risk of a rare event l ike anaphylaxis, 
and because of its low incidence, prospect ive cohort  
studies are not a very useful approach. A l though case- 
control  studies are very suitable for studying rare events, 
there were three reasons for not using this type of study. 
First, it would be difficult to f ind a control  group be 
prone to the same l ikel ihood of recal l  bias about an acute 
event such as anaphylaxis.  Second, differential  misclassi- 
f ication of exposure in the index and control  groups 
would be a possible cause of bias, because medical  prac- 
t it ioners might enquire more  insistently about the intake 
of drugs known to cause anaphylaxis.  And  third, case- 
control  studies are very effective when the associat ion 
between a rare event and the use of a drug is uncertain. 
Genera l i zed anaphylaxis,  however, is easi ly recognized 
because of the clear symptoms and signs, and its tempo-  
Table 4, Relative risk estimate of devel- 
oping anaphylaxis a  a reason for hospital 
admission 
Admissions Reimbursement figures Relative risk a 
glafenine/indomethacin 
tablets/capsules 
prescriptions 
glafenine/nitrofurantoin 
tablets/capsules 
prescriptions 
glafenine/penicillins 
tablets/capsules 
prescriptions 
nitrofurantoin/indomethacin 
tablets/capsules 
prescriptions 
nitro fur ant oin/penicillins 
tablets/capsules 
prescriptions 
penicillins/indometh acin 
tablets/capsules 
prescnptions 
glafenine/all drugs °
tablets/capsules 
prescriptions 
12/1 
12/1 
12/2 : 
12/2 : 
12/1 : 
12/1 : 
2/1 
2/1 
2/1 
2/1 
1/1 : 
1/1 : 
12/4 : 
12/4 : 
14.3/23.1 x 106 = 19.3 (4.5-82.3) b 
399/389 x 103 = 11.7 (2.4-58.2) b 
14.3/7.3 x 106 = 3.1 (0.7-12.6) 
399/172 x 103 = 2.6 (0.6-10.9) 
14.3/16.1 x 106 = 13.4 (2.8-64.1) b 
399/671 x 103 = 20.2 (4.8-84.8) b 
7.3/23.1 x 106 = 6.3 (0.8-51.3) 
172/389 x 103 = 4.5 (0.5-40.2) 
7.3/16.1 x 10 ~ = 4.4 (0.5-39.5) 
172/671 x 103 = 7.8 (1.03-59.1) b 
16.1/23.1 x 106 = 1.4 (0.1-22.6) 
671/389 x 103 = 0.6 (0.04-8.9) 
14.3/46.4 X 10 ~ = 9.7 (3.9-24.4) b
399/1232 X 103= 9.3 (3.7-23.4) b
a Relative risk = ratio of admissions due to anaphylaxis: ratio of reimbursement figures for 
index- and control drug (based on tablets/capsules and prescriptions respectively) 
b statistically significant: relative risk of unity outside 95% confidence interval 
c Indomethacin, itrofurantoin and oral penicillins 
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ral relationship to exposure, and drugs are a well-known 
and widely accepted cause of it. Thus, retrospective anal- 
ysis of all admitted cases of anaphylaxis, by relating the 
number of cases to reimbursement data, aided estimation 
of the relative risk. By estimating the risk of anaphylaxis 
to glafenine relative to other drugs, recall bias is unlikely 
to have occurred, because all patients experienced the 
same acute and serious event. The study does have some 
limitations, however, because of potential misclassifica- 
tion, potential underreporting of diagnoses, and because 
of the use of reimbursement figures. 
By validation of the clinical data, it was possible to dis- 
tinguish false-positive from true-positive cases. In the 
study 6% of the 107 likely cases had undergone false-posi- 
tive misclassification. 
Misclassification may also be negative and false-nega- 
tive. The former occurs, for instance, when urticaria as 
the only symptom isrightly classified as 'urticaria' instead 
of 'anaphylaxis'. False-negative misclassification is less 
likely but could occur when, for example, anaphylactic 
shock without a skin reaction but with diarrhoea isclassi- 
fied as gastroenteritis (ICD-code 780.2) and collapse 
(ICD-code 009.1). The second potential limitation, 
underreporting, might occur because the registration of 
additional diagnoses i not mandatory. This could mean 
that anaphylaxis occurring during admission was not al- 
ways registered. Underreporting of principal diagnoses, 
however, does not occur, and all cases of anaphylaxis 
which lead to admission will have been registered. The 
third limitation is that reimbursement data are less pre- 
cise than dispensing or consumption data. Unfortunately, 
no such data were vailable in 1981. 
None of the three above mentioned limitations jeop- 
ardized a valid estimate of the relative risk in the present 
study. False-positive misclassification was substantiated 
and was low. False-negative misclassification made it im- 
possible to estimate the incidence but not the relative risk, 
as defined above, because it is as likely to have occurred in 
both the index (glafenine) and control groups (indometh- 
acin, nitrofurantoin, oral penicillins). There would not 
have been any underreporting of the principal diagnoses, 
and since these were the main interest, underreporting did 
not prevent a valid estimation of the relative risk. Al- 
though the data from the health insurance funds are a 
proxy for consumption by the low and middle socio-eco- 
nomic classes only, it is not known how this might in- 
fluence the relative risk estimate of anaphylaxis. It must 
be admitted that the low numbers in the study made the 
estimate less precise. In our opinion, however, the high 
relative risk of developing severe anaphylaxis to gla- 
fenine, as estimated here, cannot be explained by impre- 
cise figures alone. On the contrary, there are three reasons 
to believe that the real risk of anaphylaxis to glafenine, 
relative to penicillins, is higher than was actually esti- 
mated in the study. First, the calculations were based only 
on reimbursement figures of penicillins in tablets or cap- 
sules, and not in liquid or intravenous forms. Second, as 
both prescribing doctors and pharmacists usually explain 
to patients the importance of completing an antibiotic 
course in order to prevent he risk of bacterial resistance, 
it is likely that the number of reimbursed tablets of anti- 
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biotics is a better proxy of the real number of those swal- 
lowed, than the number of reimbursed analgesic tablets. 
And third, the capacity of glafenine to induce anaphylaxis 
was emphasized inthe Dutch medical literature on several 
occasions in the period prior to 1981 [3-5]. It is not known 
whether patients with an allergic constitution react more 
readily to glafenine with anaphylaxis. If so, however, the 
relative risk might have been underestimated due to selec- 
tion bias, because there would have been a tendency not 
to prescribe glafenine to such patients. 
Anaphylaxis to glafenine has been documented on 
several occasions, mostly as descriptive studies of individ- 
ual cases [3-9]. An estimate of the frequency of the effect 
has been made, in which sales figures were related to the 
number of reports following a nationwide enquiry in 
France concerning this issue. Based on these figures, the 
frequency was 3.4cases per 100000prescriptions [9]. 
Since the enquiry might have introduced reporting bias, 
such figures should be interpreted with caution. In the 
present study reporting bias could not have played a role 
since the analysis was based on all principal diagnoses 
from all Dutch hospitals. Because anaphylaxis i easily 
recognized in most cases, we do not think that bias in rec- 
ognition distorted the results. There was no significant 
difference in severity or outcome between anaphylaxis 
due to glafenine and other causes of admission because 
of anaphylaxis. Since there are no reports uggesting that 
glafenine-induced anaphylaxis has a worse prognosis 
than anaphylaxis induced by other drugs, referral bias 
appears unlikely. 
The incidence of anaphylaxis topenicillins has been es- 
timated at 0.01% of courses [10, 11]. Based on the lower 
margin of the 95%-confidence interval of the point esti- 
mate of the relative risk in Table 4, this might mean that 
glafenine-induced anaphylaxis would have an incidence 
of approximately 1 case per 2000 courses (0.05%). It is 
emphasized that such extrapolations require cautious in- 
terpretation, since the study did not permit direct assess- 
ment of the incidence of glafenine-induced anaphylaxis. 
In conclusion, it is apparent that the risk of anaphylaxis 
to glafenine, relative to other drug-induced causes, is high. 
Although the study was performed in one country, it is 
likely that the results apply to other countries as well. The 
risk should be taken into account when deciding whether 
or not to prescribe this analgesic. 
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